| Indolent T cell lymphoproliferative disorder of the gastrointestinal tract | |
| Synonyms: | Indolent lymphoma |
| Field: | hematology and Oncology |
| Symptoms: | Common GI tract symptoms |
| Causes: | Growth of benign T cells |
| Risks: | May progress to a lymphoma |
| Differential: | Mimics certain lymphomas |
| Treatment: | None except routine follow-ups to detect malignant progression |
| Prognosis: | Guarded |
Indolent T cell lymphoproliferative disorder of the gastrointestinal tract or Indolent T cell lymphoproliferative disorder of the GI tract (ITCLD-GT) is a rare and recently recognized disorder in which mature T cell lymphocytes accumulation abnormally in the gastrointestinal tract (GI tract).[1] This accumulation causes various lesions (e.g. polyps, thickened mucosal folds, small areas of redness, and superficial ulcerations) in the mucosal layer lining the GI tract. Individuals with ITCLD-GT commonly complain of chronic GI tract symptoms such as nausea, vomiting, diarrhea, abdominal pain, and rectal bleeding.[2]
Carbonnell et al.[3] first described a case of an indolent GI tract lymphoproliferation disorder in 1994 and defined the lymphocytes involved in it to be T cells expressing the CD4 glycoprotein on their surface membranes. Subsequent studies reported on patients who had a similar indolent GI tract disorder that involved T cells which expressed either the CD4, CD8, or neither surface membrane glycoprotein. The disorder resembled certain aggressive GI tract lymphomas and was variably termed indolent lymphoma or indolent T cell lymphoproliferative disorder of the gastrointestinal tract.[4] However, the disease differed from the aggressive lymphomas which it mimicked in having a prolonged and usually non-progressive course. Furthermore, the disorder's lesions consisted of normal-appearing T cells that proliferated very slowly and usually caused little or no tissue destruction.[5] In 2017, the World Health Organization provisionally classified ITCLD-GT as an extranodal (i.e. usually not involving lymph nodes), indolent disorder in which various subtypes of T cells proliferate in the GI tract.[6]
While usually acting like a benign disease, ITCLD-GT has malignant features: 1) its normal-appearing T cells are clonal in nature, i.e. descended from a single cell;[6] 2) these T cells may contain genetic abnormalities[7] that are known to occur in and contribute to the development of very aggressive lymphomas;[8] and 3) ITCLD-GI, after many years of indolent behavior, may progress to an aggressive lymphoma.[2] Thus, ITCLD-GT can act as a premalignat disorder. Nonetheless, most cases of it run an indolent, non-malignant course and when mistakenly treated as an aggressive lymphoma, do not responded to standard chemotherapy treatments.[5] The disorder has also been mistaken for, and found unresponsive to therapies that treat inflammatory or autoimmune bowel diseases.[1] [4] Clinically, ITCLD-GT must be distinguished from the malignant, inflammatory, and autoimmune bowel diseases that it mimics in order to avoid useless and potentially harmful therapies.[5]
ITCLD-GT occurs more commonly in males of middle age (median age 48.4, range 15–77 years in one study).[2] Individuals with the disease present with GI tract symptoms which often are serious and/or debilitating and may mimic those occurring in malignant lymphoproliferative, inflammatory, or autoimmune bowel diseases.[4] These symptoms include chronic epigastric pain, abdominal pain, heartburn, nausea, diarrhea, vomiting, weight loss, relapsing oral ulcers, relapsing colorectal ulcers, rectal bleeding, and/or night sweats.[4] Several patients presenting with these symptoms have been diagnosed with and unsuccessfully treated for peripheral T-cell lymphoma,[5] an inflammatory bowel disease (either Crohn disease or ulcerative colitis),[1] or the autoimmune GI tract disorder, celiac disease.[9] It has been shown or appears very likely that these patients had ITCLD-GT rather than the cited diagnoses.[1] [5] [9]
Most patients with ITCLD-GT have chronic, relapsing and recurring GI tract symptoms that persist over many years. In one retrospective study, 19 of 23 patients with CD4+ ITCLD-GT had persistent disease over a follow-up period of 1–14 years (median 4.8 years), 2 of 23 patients had clinical and morphologic (i.e. negative GI tract evaluations) remissions enduring for at least 5–7 years, and 1 of 23 patients developed and died from a large-cell lymphoma of undetermined type. In the same study, 10 of 10 patients with CD8+ ITCLD-GT had persistent disease that had not progressed to a malignancy over an observation period of 1–18 years (median 2 years) although one patient had developed bone marrow involvement and therefore may have had disease which was in the process of transforming to a malignant state.[4] Other reports have found that the disorder in one patient with CD4-, CD8- ITCLD-GT disease progressed to involve the liver[5] and the disorder in two patients with CD4+ ITCLD-GT disease progressed to an undetermined type of large T-cell lymphoma. In another retrospective analysis, 6 of 34 (17.6%) patients with ITCLD-GT progressed to a malignant state as evidenced by its spread to the blood or bone marrow: 2 (5.6%) patients died as a direct result of this spreading.[2]
The lesions in ITCLD-GT consists of slowly growing, mature, and benign-appearing T cells. The reasons for their accumulations in the GI tract are unclear. However, these cells often carry potentially oncogenic mutations. In a recent study, the T cells in 4 of 5 patients with CD4+ T-cell disease carried a STAT3-JAK2 fusion gene.[6] This gene consists of a fusion between the STAT3 gene at position 2.2 on the long (or "g") arm of chromosome 17 (location abbreviated 17q21.2) and the JAK2 gene at position 24.1 on the short ("q") of chromosome 9 (9p24.1). The disorder in two of the patients with this t(9;17)(p24.1;q21/2) fusion gene progressed to malignant lymphomas. Abnormalities in the expression and/or activity of STAT3 and JAK2[10] as well as various JAK2 fusion genes are associated with the development and progression of various myeloproliferative and lymphoproliferative malignancies. These findings suggest that the STAT3-JAK2-fusion gene may contribute to the malignant progression and perhaps development of CD4+ ITCLD-GT. Numerous other genetic abnormalities occur in the T-cells of ITCLD-GT but unlike the STAT3-JAK fusion gene have been limited to single cases. These abnormalities include trisomy of chromosome 5, a t(4;16)(q26;p13) fusion between interleukin-2 and B-cell maturation antigen genes, loses in the 4p26 and 16p13 chromosomal areas involved in formation of the t(4;16)9q26;p13) fusion gene, and one or more copy number variations in diverse areas of different chromosomes.[4] The role(s), if any, of these abnormalities in ITCLD-GT is unclear.
The cells involved in all cases of ITCLD-GT are mature T cells[1] that exhibit a clonal rearrangement of their T-cell receptors and, therefore, are derived from a common ancestry cell.[4] They express the αβ as opposed to the γδ surface membrane T-cell receptor and therefore are αβ rather than γδ T-cells. In all reported cases, these T cells express the CD3 cluster of differentiation protein complex but vary in their expression of the CD4 cluster of differentiation glycoprotein as well as the CD8 glycoprotein component of the T cell receptor. Individuals with ITCLD-GT, therefore, have pathological accumulations of either CD4+, CD8+, or, very rarely, CD4-, CD8- T cells.[4] A single case of CD4+, CD8+ T cell disease has been reported recently.[11] There may be differences in the presentation, course, and malignant potential of ITCLD-GT based or these different expressions of CD4 and CD8 but this requires further study. Unlike certain types of T cell lymphomas for which it has been mistaken, the T cells in ITCLD-GT do not express the neutral cell adhesion molecule, CD56, and are not infected with the Epstein–Barr virus and therefore do not express this virus's latency proteins or latency ncRNAs.[1] The origin of these cells is unknown but it is thought that the CD4+ and CD8+ T-cells derive from mucosal T helper and cytotoxic T lymphocytes, respectively. The CD4-, CD8- T cells that may cause rare cases of the disorder exhibit cytology and morphology features of both of the latter two mucosal cell types.[4]
Histological analysis of tissues biopsied from the GI tract generally reveals dense infiltrates of small, mature lymphocytes in the mucosa that may displace[2] but usually do not invade[4] the epithelium; these cells sometimes extend through the muscularis mucosa to invade the submucosa.[4] The lesions may contain reactive plasma cells, eosinophils, granulomas (in CD4+ disease), and lymphoid follicles.[2] There is little or no tissue destruction.[1] Immunohistochemistry analyses indicate that the small lymphocytes are CD4+,[11] CD8+,[11] CD4-/CD8-,[4] or CD4+/CD8+ T-cells[11] that stain for CD3[4] but not CD56 or Epstein-Barr virus products.[1] Notably, the affected T cells have an extremely low rate of proliferation as determined by examining their KI-67 protein using immunofluorescence analysis.[4]
The diagnosis of indolent T cell lymphoproliferative disorder of the GI tract depends on identifying the presentation, clinical course, and laboratory and histological findings given in the previous four sections.[4] (Future studies may find that the diagnosis is supported by demonstrating the presence of the STAT3-JAK2 fusion gene in the CD4+ T cells of suspicious tissues.[6])
Inspection of the entire GI tract by endoscopy and colonoscopy generally finds mucosal redness, erosions, small superficial ulcerations, occasional small polyps,[2] fissures, diverticula, and, rarely, tumor-like masses and deep ulcers.[4] These lesions may be localized, occur in multiple sites, or extend throughout the GI tract;[4] they are more common in the small intestine and colon[2] but can also occur in the stomach, esophagus, oral cavity (e.g. palate), and rectum.[4] Whole body computed tomography scans (i.e. CT scans) frequently find enlarged mesenteric lymph nodes (i.e. lymph nodes attached to the intestinal mesentery) and may show evidence of liver, spleen, and/or other organ involvement in cases which are advancing or have advanced to a malignant lymphoma. Positron emission tomography scans (i.e. PET scans) and positron emission tomography–computed tomography scans (i.e. PET-CT scans) likewise often show that the mesenteric lymph nodes in ITCLD-GT exhibit modestly increased metabolic or biochemical activity and, in cases of progressing or overt malignant disease, show increased activity in other organs.[4] Inspection of patients' peripheral blood smearss and bone marrow tissues may identify excessive numbers of ITCLD-GT's T cells and thereby likewise indicate progressing or malignant disease.[2]
Because of the radical differences in their prognoses and treatments, ITCLD-GT should be distinguished from the malignant, inflammatory, autoimmune, and other diseases that it can mimic. Key findings that distinguish ITCLD-GT from the following major diseases which ITCLD-GT may mimic are:
Studies indicate that patients with ITCLD-GT should be treated conservatively. Chemotherapy regimens directed at malignant lymphoma and treatment regimens used to treat celiac disease, Crohn's disease, or ulcerative colitis have had little or no beneficial effects on the course of the disease.[4] Patients should be follow regularly with peripheral blood and bone marrow examinations, GI tract endoscopic examinations[4] and PET scans[2] in order to detect the progression of ITCLD-GT to a malignant phase.
Studies to date indicate that most patients experience a prolonged course of persistent or recovering-relapsing GI tract symptoms. A small percentage of patients have had spontaneous and sustained recoveries or progressed to a malignant lymphoma.[4]